About SMA:
SMA Press
About SMA: SMA Press
The SMA Foundation’s partners, Roche and PTC Therapeutics, announced today that the FDA has approved a label extension for Evrysdi(risdiplam) to include babies under two months old with SMA. The approval is based on interim efficacy and safety data from the RAINBOWFISH study in newborns, which showed that pre-symptomatic babies treated with Evrysdi for at least one…
Read MoreToday Scholar Rock shared a community update on SAPPHIRE, a clinical trial evaluating apitegromab in non-ambulatory patients with Type 2 and 3 SMA: Dear SMA Community, We are excited to announce the design of SAPPHIRE, a Phase 3 clinical trial to further evaluate the safety and efficacy of apitegromab in those living with Spinal Muscular…
Read MoreBiogen and Ionis have taken a crucial step in the pathway to approval of nusinersen. Biogen has completed the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) and will submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the coming weeks. Biogen has also applied…
Read MoreRoche has announced that the company is initiating two new Phase 2 studies in patients with Spinal Muscular Atrophy (SMA) to evaluate RG7916—SUNFISH and FIREFISH. RG7916 is an orally available drug that directly targets the underlying molecular deficiency of SMA by modulating SMN2 splicing to increase expression of full-length SMN2 mRNA and SMN protein from…
Read MoreSince grade school, Lauren Gibbs had been a dogged defensive player on her wheelchair-basketball team. Offense wasn’t a big part of her game because it was a struggle to heave the ball high enough to hit the rim. Then Gibbs, who was born with spinal muscular atrophy, enrolled in a trial of an experimental drug…
Read MoreCAMBRIDGE, Mass. & CARLSBAD, Calif.–Aug. 1, 2016– Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) today announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen in infantile-onset (consistent with Type 1) SMA. The analysis found that infants receiving…
Read MoreIn May, we shared with you news of the difficult decision to pause enrollment for our study of LMI070 for the treatment of Type 1 Spinal Muscular Atrophy (SMA). This decision was made because results from an animal study, using daily dosing for a year compared to weekly dosing in the human study, showed unexpected…
Read MoreChicago,Ill., July 20, 2016 – AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for AVXS-101, the company’s lead development candidate for the treatment of spinal muscular atrophy (SMA) Type 1…
Read MoreWednesday May 25th, 2016 – Letter from Novartis: We have made the difficult decision to pause enrollment for our study of LMI070 for the treatment of Type 1 Spinal Muscular Atrophy (SMA). Animal safety studies were taking place in parallel with this trial, which is a common practice when studying potentially life threatening diseases to…
Read MoreWASHINGTON, D.C., May 26, 2016–FightSMA is proud to announce that, for the first time, the U.S. Senate Appropriations committee has included spinal muscular atrophy as a research topic in the Defense Department’s Peer-Reviewed Medical Research Program as part of the Fiscal Year 2017 Defense Appropriations bill. This exciting news comes as the result of months…
Read More-Phase 1 Study Initiated in Healthy Volunteers with New SMN2 Splicing Modifier – RG7916 – SOUTH PLAINFIELD, N.J., Jan. 7, 2016 /PRNewswire/ — PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that RG7916, an additional SMN2 splicing modifier from the company’s joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA), has…
Read MoreBrighton, United Kingdom. October 5, 2015 – AveXis, Inc., a clinical stage gene therapy company developing treatments for rare and life-threatening neurological genetic diseases, presented data from its ongoing Phase 1/2 trial of AVXS-101, the company’s initial product candidate for the treatment of spinal muscular atrophy (SMA) Type 1, at the International Congress of the…
Read More